-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 24, Yiling Pharmaceutical announced that it received the "Drug Supplementary Application Approval Notice" for dextromethorphan hydrobromide tablets approved and issued by the National Medical Products Administration.
Dextromethorphan Hydrobromide Tablets is a central antitussive used for dry coughs, including coughs caused by upper respiratory tract infections (such as colds and pharyngitis), bronchitis, etc.
Coughs caused by colds and pharyngitis), bronchitis, etc.
, belong to the category B species of the National Medical Insurance Catalog (2020 version).
At present, only 2 dextromethorphan hydrobromide tablets in China have passed the consistency evaluation (including the products approved by the company this time ).